Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
We employ our advanced, specialised process to create targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.
Several key aspects differentiate our library:
partner
Reaxense
upacc
Q969Z4
UPID:
TR19L_HUMAN
Alternative names:
Receptor expressed in lymphoid tissues
Alternative UPACC:
Q969Z4; Q86V34; Q96JU1; Q9BUX7
Background:
Tumor necrosis factor receptor superfamily member 19L, alternatively known as Receptor expressed in lymphoid tissues, plays a pivotal role in apoptosis and is implicated in dental enamel formation. Its involvement in activating MAPK14/p38 and MAPK8/JNK MAPK cascades upon overexpression highlights its significance in cellular signaling pathways.
Therapeutic significance:
Linked to Amelogenesis imperfecta 3C, a genetic condition affecting enamel formation, understanding the role of Tumor necrosis factor receptor superfamily member 19L could open doors to potential therapeutic strategies for improving dental health and treating enamel hypocalcification.